Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSamuel Heath Regulatory News (HSM)

Share Price Information for Samuel Heath (HSM)

Share Price is delayed by 15 minutes
Get Live Data
325.00    0.00 (0.00%)
Bid:
310.00
Ask:
340.00
Spread: 30.00 (9.677%)
Market Cap: £8.24m
HSM Live PriceLast checked at - London Stock Exchange

Intraday Samuel Heath Share Chart

Half-year Report

12 Nov 2021 07:00

RNS Number : 1386S
Heath(Samuel) & Sons PLC
12 November 2021
Β 

SAMUEL HEATH & SONS plc

("the Company")

Β 

UNAUDITED INTERIM REPORT

Β 

Half year ended 30 September 2021

Β 

CHAIR'S STATEMENT

Β 

This is my first statement as Chair following the passing of Sam Heath. Sam had an enormous influence on the Company over his working life and we will greatly miss him. He has however left behind a strong board of directors and senior executive team.

Β 

Our trading performance for the six months to 30 September 2021 reflected the successful navigation of the Company from the destabilising effects of the global Covid-19 virus and related lockdowns. Profit before tax of Β£776k was achieved compared to a Β£224k loss before tax after exceptional items in the Covid impacted period ended 30 September 2020 and a profit of Β£363k in the pre-Covid period ended 30 September 2019. Sales recovered to Β£6.9 million (2020: Β£4.9m and 2019: Β£6.9m), with performance continuing to improve as the pandemic restrictions eased. The primary driver of improved profitability was a post-Covid 'bounce' in sales and strong order book growth. We were also able to avoid any significant export logistical issues. The increase in sales was achieved while maintaining much of the cost savings implemented during lockdown, thereby improving margins. The UK Government furlough scheme made a very minor contribution. This brought our total half year results to a profit after tax of Β£651k (2020: loss after tax of Β£181k).

Β 

Looking forward to the second six months of the year, we have entered the period with solid momentum and a healthy order book. However, there is uncertainty regarding how long the Covid bounce will last and whether a Covid resurgence over the winter could cause renewed disruption to sales and operations. So far, we have managed supply disruptions well, raising stock levels where prudent or finding alternative sources. However, there remains the possibility that we will struggle to source some materials, as a result of further import disruption and the knock-on effects of high energy costs and interrupted transport logistics. So, all in all, it is not possible to predict with confidence that the second half will match the first half performance.

Β 

In the light of the performance recovery in the first half, we have decided to resume payment of an interim dividend of 5.5p per share (2020: nil), the same level as in 2019, which will be paid on 25 March 2022 to shareholders registered as at 25 February 2022.

Β 

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

Β 

Anthony Buttanshaw

Chair

11 November 2021

For further information, please contact:

Samuel Heath & Sons Plc

Simon Latham, Company Secretary 0121 766 4200

Β 

Cairn Financial Advisers LLP

James Caithie / Jo Turner 020 7213 0880

Β 

Unaudited Interim Financial Report

For the Half Year ended 30 September 2021

Β 

CONSOLIDATED INCOME STATEMENT

Β 

Β 

Β 

Β 

Β 

Β 

Half year

Β 

Half year

Β 

Year

Β 

ended 30

Β 

ended 30

Β 

ended 31

Β 

September

Β 

September

Β 

March

Β 

2021

Β 

2020

Β 

2021

Β 

Unaudited

Β 

Unaudited

Β 

Audited

Β 

Β£'000

Β 

Β£'000

Β 

Β£'000

Β 

Β 

Β 

Β 

Β 

Β 

Revenue

6,904

Β 

4,850

Β 

11,539

Β 

Β 

Β 

Β 

Β 

Β 

Cost of sales

(3,510)

Β 

(3,062)

Β 

(6,568)

Β 

Β 

Β 

Β 

Β 

Β 

Gross profit

3,394

Β 

1,788

Β 

4,971

Β 

Β 

Β 

Β 

Β 

Β 

Selling and distribution costs

(1,510)

Β 

(1,344)

Β 

(2,469)

Administrative expenses

(1,052)

Β 

(940)

Β 

(2,004)

Other operating income - grants (note 6)

16

Β 

596

Β 

625

Β 

Β 

Β 

Β 

Β 

Β 

Operating profit before exceptional items

848

Β 

100

Β 

1,123

Β 

Β 

Β 

Β 

Β 

Β 

Exceptional items - GMP equalisation

-

Β 

-

Β 

(70)

Reorganisation

-

Β 

(230)

Β 

(252)

Β 

Β 

Β 

Β 

Β 

Β 

Operating profit

848

Β 

(130)

Β 

801

Β 

Β 

Β 

Β 

Β 

Β 

Finance income

10

Β 

Β 14

Β 

4

Finance cost

(82)

Β 

(108)

Β 

(185)

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Profit/(loss) before taxation

776

Β 

(224)

Β 

620

Β 

Β 

Β 

Β 

Β 

Β 

Taxation

(125)

Β 

43

Β 

(227)

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Profit/(loss) for the period

Β 

651

Β 

Β 

(181)

Β 

Β 

393

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Basic and diluted earnings /(loss) per ordinary share (note 4)

25.7p

Β 

(7.1p)

Β 

15.5p

Β 

Β 

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Half year ended 30 September

Β 

Half year ended 30 September

Β 

Year ended 31 March

Β 

Β 

2021

Β 

2020

Β 

2021

Β 

Unaudited

Β 

Unaudited

Β 

Audited

Β 

Β£'000

Β 

Β£'000

Β 

Β£'000

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Profit/(loss) for the period

651

Β 

(181)

Β 

393

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Items that will not be reclassified to profit or loss:

Β 

Β 

Β 

Β 

Β 

Actuarial (loss) on defined benefit pension scheme

(316)

Β 

Β (1,239)

Β 

(542)

Deferred tax on actuarial loss

60

Β 

218

Β 

103

Deferred tax rate change

298

Β 

-

Β 

-

Β 

Β 

Β 

Β 

Β 

Β 

Β 

42

Β 

(1,021)

Β 

(439)

Β 

Β 

Β 

Β 

Β 

Β 

Total comprehensive income for the period

693

Β 

(1,202)

Β 

(46)

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

Β 

At 30 September

Β 

Β At 30 September

Β 

At 31 March

Β 

Β 

2021

Β 

2020

Β 

2021

Β 

Β 

Unaudited

Β 

Unaudited

Β 

Audited

Β 

Β£'000

Β 

Β£'000

Β 

Β£'000

Non-current assets

Β 

Β 

Β 

Β 

Β 

Intangible assets

191

Β 

135

Β 

186

Property, plant and equipment

3,345

Β 

3,541

Β 

3,413

Deferred tax assets

997

Β 

1,103

Β 

741

Β 

Β 

Β 

Β 

Β 

Β 

Β 

4,533

Β 

4,779

Β 

4,340

Β 

Β 

Β 

Β 

Β 

Β 

Current assets

Β 

Β 

Β 

Β 

Β 

Inventories

3,718

Β 

3,869

Β 

3,682

Trade and other receivables

2,113

Β 

1,689

Β 

2,108

Current tax receivable

-

Β 

-

Β 

25

Cash and cash equivalents

4,909

Β 

3,424

Β 

3,682

Β 

10,740

Β 

8,982

Β 

9,497

Β 

Β 

Β 

Β 

Β 

Β 

Total assets

15,273Β 

Β 

13,761

Β 

13,837

Β 

Β 

Β 

Β 

Β 

Β 

Current liabilities

Β 

Β 

Β 

Β 

Β 

Trade and other payables

(1,862)

Β 

(1,772)

Β 

(1,769)

Right of use lease liabilities

(26)

Β 

(53)

Β 

(55)

Borrowings (note 7)

(84)

Β 

-

Β 

-

Current tax payable

(101)

Β 

(36)

Β 

-

Β 

(2,073)

Β 

(1,861)

Β 

(1,824)

Β 

Β 

Β 

Β 

Β 

Β 

Non-current liabilities

Β 

Β 

Β 

Β 

Β 

Right of use lease liabilities

-

Β 

(26)

Β 

-

Borrowings (note 7)

(866)

Β 

-

Β 

-

Retirement benefit scheme

(6,198)

Β 

(7,413)

Β 

(6,396)

Β 

(7,064)

Β 

(7,439)

Β 

(6,396)

Β 

Β 

Β 

Β 

Β 

Β 

Total liabilities

(9,137)

Β 

(9,300)

Β 

(8,220)

Β 

Β 

Β 

Β 

Β 

Β 

Net assets

6,136

Β 

4,461

Β 

5,617

Β 

Β 

Β 

Β 

Β 

Β 

Equity

Β 

Β 

Β 

Β 

Β 

Called up share capital

254Β 

Β 

254

Β 

254

Capital redemption reserve

109

Β 

109

Β 

109

Revaluation reserve

Retained earnings

1,225

4,548Β 

Β 

1,308

2,790

Β 

1,267

3,987

Β 

Β 

Β 

Β 

Β 

Β 

Equity shareholders' funds

6,136

Β 

4,461

Β 

5,617

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β Β Β Β Β Β Β 

Β 

Β 

Β 

Β 

Β 

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

Attributable to owners of the Parent Company

Β 

Β 

Share capital

Capital redemption reserve

Revaluation reserve

Retained earnings

Total equity

Β 

Β£000

Β£000

Β£000

Β£000

Β£000

Β 

Β 

Β 

Β 

Β 

Β 

Balance at 31 March 2020

254

109

1,349

3,951

5,663

Β 

Total transactions with owners

Β 

Β 

Β 

Β 

Β 

Equity dividends paid

-

-

-

-

Β -

Β 

Β 

Β 

Β 

Β 

Β 

Loss for the period

-

-

-

(181)

(181)

Other comprehensive income for the period

Reclassification of depreciation on revaluation

Β 

-

Β 

-

-

Β 

-

-

Β 

(41)

(1,021)

Β 

41

(1,021)

Β 

-

Total comprehensive income for the period

-

-

(41)

(1,161)

(1,202)

Β 

Β 

Β 

Β 

Β 

Β 

Balance at 30 September 2020

254

109

1,308

2,790

4,461

Β 

Total transactions with owners

Β 

Β 

Β 

Β 

Β 

Equity dividends paid

-

-

-

-

-

Β 

Β 

Β 

Β 

Β 

Β 

Profit for the period

-

-

-

574

574

Other comprehensive income for the period

Reclassification of depreciation on revaluation

Β 

-

Β 

-

-

Β 

-

-

Β 

(41)

582

Β 

41

582

Β 

-

Total comprehensive income for the period

-

-

(41)

1,197

1,156

Β 

Β 

Β 

Β 

Β 

Β 

Balance at 31 March 2021

254

109

1,267

3,987

5,617

Β 

Β 

Β 

Β 

Β 

Β 

Total transactions with owners

Equity dividends paid

-

-

-

(174)

(174)

Β 

Β 

Β 

Β 

Β 

Β 

Profit for the period

-

-

-

651

651

Other comprehensive income for the period

Reclassification of depreciation on revaluation

Β 

-

Β 

-

-

Β 

-

-

Β 

(42)

42

Β 

42

42

Β 

-

Total comprehensive income for the period

-

-

(42)

735Β 

693

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Balance at 30 September 2021

254

109

1,225

4,548

6,136

Β 

Β 

Β 

Β 

Β 

Β 

CONSOLIDATED CASH FLOW STATEMENT

Β 

Β 

Half year ended 30 September

Β 

Half year ended 30 September

Β 

Year ended 31 March

Β 

2021

Β 

2020

Β 

2021

Β 

Unaudited

Β 

Unaudited

Β 

Audited

Β 

Β£'000

Β 

Β£'000

Β 

Β£'000

Cash flow from operating activities

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Profit/(loss) for the period before taxation

776

Β 

(224)

Β 

620

Β 

Β 

Β 

Β 

Β 

Β 

Adjustments for:

Β 

Β 

Β 

Β 

Β 

Depreciation

150

Β 

155

Β 

370

Amortisation

24

Β 

16

Β 

45

Loss/(profit) on disposal of property, plant and equipment

10

Β 

-

Β 

(41)

Net finance costs/(income)

(10)

Β 

(14)

Β 

21

Defined benefit pension scheme expenses

106

Β 

98

Β 

280

Contributions to defined benefit pension scheme

(518)

Β 

(500)

Β 

(1,000)

Β 

Β 

Β 

Β 

Β 

Β 

Operating cash flow before movements in working capital

538

Β 

(469)

Β 

295

Β 

Β 

Β 

Β 

Β 

Β 

Changes in working capital:

Β 

Β 

Β 

Β 

Β 

(Increase)/decrease in inventories

(36)

Β 

Β 361

Β 

548

(Increase)/decrease in trade and other receivables

(33)Β 

Β 

658

Β 

262

Increase/(decrease) in trade and other payables

124

Β 

(65)

Β 

(65)

Β 

Β 

Β 

Β 

Β 

Β 

Cash generated from operations

593

Β 

485

Β 

1,040

Β 

Β 

Β 

Β 

Β 

Β 

Taxation paid

-

Β 

-

Β 

(109)

Β 

Β 

Β 

Β 

Β 

Β 

Net cash from operating activities

593

Β 

485

Β 

931

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Cash flow from investing activities

Β 

Β 

Β 

Β 

Β 

Payments to acquire property, plant and equipment

(93)

Β 

(61)

Β 

(169)

Proceeds from the sale of property, plant and equipment

-

Β 

-

Β 

63

Payments to acquire intangible assets

(29)

Β 

-

Β 

(79)

Net finance income/(costs)

10

Β 

14

Β 

(21)

Β 

Β 

Β 

Β 

Β 

Β 

Net cash outflow from investing activities

(112)

Β 

(47)

Β 

(206)

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Cash flow from financing activities

Β 

Β 

Β 

Β 

Β 

Payment for right of use assets

(30)

Β 

(30)

Β 

(59)

Proceeds from new loans (note 7)

950

Β 

-

Β 

-

Dividends paid

(174)

Β 

-

Β 

-

Β 

Β 

Β 

Β 

Β 

Β 

Net cash outflow from financing activities

746

Β 

(30)

Β 

(59)

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Net increase in cash and cash equivalents

1,227

Β 

408

Β 

666

Β 

Cash and cash equivalents at beginning of period

3,682

Β 

3,016

Β 

3,016

Β 

Β 

Β 

Β 

Β 

Β 

Cash and cash equivalents at end of period

4,909

Β 

3,424

Β 

3,682

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

NOTES TO THE INTERIM FINANCIAL REPORT

Β 

Β 

1. BASIS OF PREPARATION OF INTERIM REPORT

As permitted, IAS34 'Interim Financial Reporting' has not been applied in this interim report. The information for the period ended 30 September 2021 is not audited and does not constitute statutory accounts as defined in section 434 of the Companies Act 2006. The statutory accounts for the year ended 31 March 2021 were given an unqualified audit report and did not contain statements under section 498(2) or 498(3) of the Companies Act 2006. A copy of the statutory accounts for that year has been delivered to the Registrar of Companies. The interim accounts for the half year ended 30 September 2020 were also unaudited.

2. ACCOUNTING POLICIES

Basis of accounting

The report has been prepared on a going concern basis in accordance UK-adopted International Accounting Standards.

Β 

The group has not availed itself of early adoption options in standards and interpretations.

Β 

The principal accounting policies adopted are as set out in the Annual Report for the year ended 31 March 2021. The valuation of inventories is considered to be the main area in terms of significant accounting estimates and judgements.

The retirement benefit scheme liability recognised in these interim accounts reflects the estimated change in the deficit at 30 September 2021 from the movements in discount rates and inflation during the six months.

3. DIVIDENDS

Β 

A final dividend for the financial year 2021 of 6.875p per share (2020: 0.0p) was paid during the period.

An Interim dividend for the financial year 2022 of 5.5p per share is proposed (2021: 0.0p), payable on 25 March 2022.

4. EARNINGS/(LOSS) PER SHAREΒ 

The basic and diluted earnings per share are calculated by dividing the relevant profit after taxation of Β£651,000 (2020: loss Β£181,000) by the average number of ordinary shares in issue during the period being 2,534,322 (2020: 2,534,322). The number of shares used in the calculation is the same for both basic and diluted earnings.

5. EXCEPTIONAL ITEMS

In November 2020, there was a further High Court ruling in relation to guaranteed minimum pension benefits. The latest ruling states that trustees of defined benefit schemes that provided guaranteed minimum payments should revisit, and where necessary, top-up historic cash equivalent transfer values that were calculated on an unequalised basis if an affected member makes a successful claim. The impact of the ruling implies that pension scheme trustees are responsible for equalising the guaranteed minimum payments for members who transferred out of its defined benefit pension scheme. This has resulted in an increase in the liabilities of the scheme of Β£70,000 for the year ended 31 March 2021 (half years ended 30 September 2020 and 30 September 2021: Β£nil), which was recognised in the results as a past service cost in exceptional items.

Included within exceptional costs are the costs of restructuring the business to size itself better in the year ended 31 March 2021. Costs for exceptional redundancy in the half year ended 30 September 2021 were Β£nil (year ended 31 March 2021: Β£252,000; half year ended 30 September 2020: Β£230,000).

Β 

Β 

NOTES TO THE INTERIM FINANCIAL REPORT (continued)

Β 

6. OTHER OPERATING INCOME - GRANT FUNDING

Income has been received from government grants providing support during the Coronavirus pandemic:

Half year ended 30 September

Β 

Half year ended 30 September

Β 

Year ended 31 March

Β 

2021

Β 

2020

Β 

2021

Β 

Unaudited

Β 

Unaudited

Β 

Audited

Β 

Β£'000

Β 

Β£'000

Β 

Β£'000

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Job Retention Scheme

16

Β 

Β 571

Β 

600

Borough of Hammersmith & Fulham

-Β 

Β 

25

Β 

25

Β 

Β 

Β 

Β 

Β 

Β 

Total other operating income

16

Β 

596

Β 

625

Β 

Β 

Β 

Β 

Β 

Β 

Income has been accounted for under the accruals method.

Β 

Β 

7. BORROWINGS

Β 

At the end of April 2021, the Company drew down a loan under the Coronavirus Business Interruption Loan Scheme (CBILS), for the value of Β£950,000, which under the standard terms is interest free for 12 months, with no penalty for early repayment.

Β 

Β 

Note:

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not a guarantee of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
IR BUBDBUXBDGBB
Date   Source Headline
1st Apr 20267:00 amRNSDirectorate change
3rd Feb 20263:01 pmRNSRetirement of Director
26th Nov 202512:00 pmRNSHalf-year Report
11th Sep 20252:22 pmRNSResult of AGM
25th Jul 20258:35 amRNSFinal Results & Notice of AGM
4th Feb 20253:15 pmRNSChange of Auditor
26th Nov 20247:00 amRNSHalf-year Report
5th Sep 20244:38 pmRNSResult of AGM
7th Aug 20247:00 amRNSFinal Results
21st Nov 20237:00 amRNSHalf-year Report
7th Sep 20231:53 pmRNSResult of AGM
21st Jul 20237:00 amRNSFinal Results
9th Dec 20221:48 pmRNSHolding(s) in Company
9th Dec 20221:45 pmRNSDirector/PDMR Shareholding
18th Nov 20227:00 amRNSHalf-year Report
25th Aug 20223:08 pmRNSResult of AGM
20th Jul 202212:40 pmRNSReplacement: Final Results
20th Jul 20227:00 amRNSFinal Results
12th Nov 20217:00 amRNSHalf-year Report
6th Aug 20211:35 pmRNSResult of AGM
19th Jul 202110:14 amRNSDirectorate Change
8th Jul 20212:34 pmRNSFinal Results
30th Dec 20207:00 amRNSDirectorate Change
12th Nov 20207:00 amRNSHalf-year Report
7th Aug 20202:35 pmRNSResult of AGM
10th Jul 20207:30 amRNSFinal Results
9th Jul 20204:13 pmRNSHolding(s) in Company
8th Apr 20203:40 pmRNSCOVID-19 Trading Update
6th Feb 20207:00 amRNSDirectorate Change
18th Dec 20197:00 amRNSDirector/PDMR Shareholding
10th Dec 20199:53 amRNSDirectorate Change
15th Nov 20197:00 amRNSHalf-year Report
9th Aug 20192:45 pmRNSResult of AGM
15th Jul 20194:38 pmRNSHolding(s) in Company
11th Jul 20197:00 amRNSFinal Results
1st Apr 201911:47 amRNSPDMR/PCA Dealing
8th Nov 20187:00 amRNSHalf-year Report
10th Aug 20181:01 pmRNSResult of AGM
12th Jul 20183:26 pmRNSFinal Results
15th Jan 201811:13 amRNSDividend Record Date
9th Nov 20177:00 amRNSHalf-year Report
13th Oct 20179:45 amRNSHolding(s) in Company
13th Oct 20179:43 amRNSHolding(s) in Company
29th Sep 20177:00 amRNSDirectorate Change
1st Sep 20179:22 amRNSDirectorate Change
14th Aug 201711:48 amRNSResult of AGM
12th Jul 20179:33 amRNSFinal Results
16th Jun 20177:00 amRNSDirector/PDMR Shareholding - Replacement
10th May 20172:34 pmRNSDirector/PDMR Shareholding
7th Mar 20173:36 pmRNSDirector/PDMR Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.